Log in
NYSE:GKOS

Glaukos Stock Forecast, Price & News

$70.23
-0.64 (-0.90 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$67.81
Now: $70.23
$71.29
50-Day Range
$22.99
MA: $59.18
$70.87
52-Week Range
$23.31
Now: $70.23
$71.96
Volume437,329 shs
Average Volume694,016 shs
Market Capitalization$3.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.85
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; iDose Travoprost, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication; and MicroShunt, an ab-externo device for treatment of open-angle glaucoma. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.
Glaukos logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.90 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone949-367-9600
Employees600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$236.98 million
Cash Flow$0.17 per share
Book Value$14.71 per share

Profitability

Net Income$15.42 million

Miscellaneous

Market Cap$3.16 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$70.23
-0.64 (-0.90 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GKOS News and Ratings via Email

Sign-up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Glaukos (NYSE:GKOS) Frequently Asked Questions

How has Glaukos' stock price been impacted by Coronavirus?

Glaukos' stock was trading at $38.64 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GKOS stock has increased by 81.8% and is now trading at $70.23.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Glaukos?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 2 sell ratings, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Glaukos
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Glaukos?

Wall Street analysts have given Glaukos a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Glaukos wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Glaukos' next earnings date?

Glaukos is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Glaukos
.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) posted its earnings results on Thursday, November, 5th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.46) by $0.37. The medical instruments supplier earned $64.83 million during the quarter, compared to analyst estimates of $53.74 million. Glaukos had a negative return on equity of 7.99% and a negative net margin of 33.61%. The business's revenue for the quarter was up 10.8% on a year-over-year basis. During the same period in the previous year, the company earned ($0.10) earnings per share.
View Glaukos' earnings history
.

What price target have analysts set for GKOS?

8 analysts have issued 12 month price targets for Glaukos' shares. Their forecasts range from $36.00 to $70.00. On average, they anticipate Glaukos' stock price to reach $52.75 in the next twelve months. This suggests that the stock has a possible downside of 24.9%.
View analysts' price targets for Glaukos
.

Are investors shorting Glaukos?

Glaukos saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 4,990,000 shares, a decrease of 12.8% from the October 31st total of 5,720,000 shares. Based on an average trading volume of 581,300 shares, the short-interest ratio is currently 8.6 days.
View Glaukos' Short Interest
.

Who are some of Glaukos' key competitors?

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology Group (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and The Boeing (BA).

Who are Glaukos' key executives?

Glaukos' management team includes the following people:
  • Mr. Thomas William Burns, CEO, Pres & Director (Age 59, Pay $649.24k)
  • Mr. Joseph E. Gilliam, CFO & Sr. VP of Corp. Devel. (Age 44, Pay $696.83k)
  • Mr. Chris M. Calcaterra, Chief Operating Officer (Age 60, Pay $693.33k)
  • Dr. Mory Gharib Ph.D., Co-Founder
  • Mr. Christopher William Lewis, Director of Investor Relations, Corp. Strategy & Devel.
  • Ms. Diane W. Biagianti, Sr. VP & Gen. Counsel
  • Ms. Michele M. Allegretto, Sr. VP of HR
  • Mr. David S. Haffner, Sr. VP of New Technologies
  • Mr. L. Jay Katz M.D., FACS, Chief Medical Officer
  • Ms. Jane E. Rady, Sr. VP of Corp. Strategy & Bus. Devel. (Age 72)

When did Glaukos IPO?

(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Who are Glaukos' major shareholders?

Glaukos' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.80%), State Street Corp (3.20%), New York State Common Retirement Fund (2.32%), Natixis (1.47%), First Light Asset Management LLC (1.45%) and Wasatch Advisors Inc. (1.16%). Company insiders that own Glaukos stock include Chris M Calcaterra, David First, Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends for Glaukos
.

Which institutional investors are selling Glaukos stock?

GKOS stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, BNP Paribas Arbitrage SA, State of Tennessee Treasury Department, Blair William & Co. IL, State of New Jersey Common Pension Fund D, UBS Asset Management Americas Inc., Envestnet Asset Management Inc., and Truist Financial Corp. Company insiders that have sold Glaukos company stock in the last year include Thomas William Burns, and William J Phd Link.
View insider buying and selling activity for Glaukos
.

Which institutional investors are buying Glaukos stock?

GKOS stock was purchased by a variety of institutional investors in the last quarter, including Natixis, Point72 Asset Management L.P., JPMorgan Chase & Co., New York State Common Retirement Fund, BlackRock Inc., Morgan Stanley, Great West Life Assurance Co. Can, and SG Americas Securities LLC. Company insiders that have bought Glaukos stock in the last two years include David First, and Gilbert H Kliman.
View insider buying and selling activity for Glaukos
.

How do I buy shares of Glaukos?

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $70.23.

How big of a company is Glaukos?

Glaukos has a market capitalization of $3.16 billion and generates $236.98 million in revenue each year. The medical instruments supplier earns $15.42 million in net income (profit) each year or ($0.10) on an earnings per share basis. Glaukos employs 600 workers across the globe.

What is Glaukos' official website?

The official website for Glaukos is www.glaukos.com.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.